Reblozyl 25mg, a treatment for patients with beta-Mediterranean anemia, was officially approved for items a year after designation as a rare drug.

The MFDS approved Reblozyl applied by BSM Pharmaceutical Korea.

Reblozyl is equipped with▲ the treatment of adult beta-Mediterranean anemia patients who need red blood cell transfusion as an indication, and ▲MDS-RS with minimum, low, and moderate risk of ring ferrous hematopoietic stem cell or low, moderate risk of ring ferrous hematopoietic and thrombocytopenia with increased myelogenesis/myeloproliferative tumor (MDS/NMP-T)

Reblozyl was designated as a rare drug on April 1 last year. Beta-Mediterranean anemia, also called Coo